awmsg logo



fampridine (Fampyra®)


Reference No. 3942

Publication date:
13/12/2019


Appraisal information

fampridine (Fampyra®) 10 mg prolonged-release tablet


Company: Biogen Idec Ltd
BNF category: Central nervous system
NMG meeting date: 06/11/2019
AWMSG meeting date: 11/12/2019
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1919
Ratification by Welsh Government: 12/12/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Fampridine (Fampyra®) is recommended as an option for use within NHS Wales for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale [EDSS] 4 to 7). This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download